Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-Blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)

Trial Profile

A Randomised, Double-Blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2018

At a glance

  • Drugs Ticagrelor (Primary) ; Clopidogrel
  • Indications Acute coronary syndromes; Cardiovascular disorders
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms PLATO
  • Sponsors AstraZeneca
  • Most Recent Events

    • 29 Aug 2018 Results presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology
    • 29 Aug 2018 Results of the biomarker substudy assessing the associations between multiple biomarkers and cause-specific mortality (n=17905) presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology
    • 20 Aug 2018 According to AstraZeneca media release, data from this trial will be prestentd at the European Society of Cardiology (ESC) Congress .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top